Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Sirtex Medical Limited		
ABN 35 078 166 122		

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Gilman Wong
Date of last notice	8 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct
N/A
20 May 2016
140,000 Ordinary Shares held directly by G. Wong 20,000 Ordinary Shares held by GEW
Superannuation Fund
188,000 Performance Rights held directly
by G. Wong
Performance Rights
45,930 Performance Rights
Nil
Nil
140,000 Ordinary Shares held directly by G. Wong 20,000 Ordinary Shares held by GEW Superannuation Fund 233,930 Performance Rights held directly by G. Wong

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options,	Issue of Performance Rights
issue of securities under dividend reinvestment plan, participation in buy-back	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.